<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9245">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05702073</url>
  </required_header>
  <id_info>
    <org_study_id>INS068-301</org_study_id>
    <nct_id>NCT05702073</nct_id>
  </id_info>
  <brief_title>To Compare the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin.</brief_title>
  <official_title>A Randomized, Open-Label, Controlled, Parallel-group, Multicenter Trial Comparing the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Not Adequately Controlled With Basal Insulin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to evaluate the efficacy and safety of INS068 once daily (QD) in subjects with&#xD;
      type 2 diabetes not adequately controlled with basal insulin compared to insulin Glargine QD&#xD;
      for 26weeks.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 31, 2023</start_date>
  <completion_date type="Anticipated">October 23, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 23, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, Open-Label, Controlled, Parallel-group, Multicenter Trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HbA1c</measure>
    <time_frame>Week 0 to Week 26</time_frame>
    <description>Change from baseline in Glycosylated Haemoglobin after 26 weeks of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in FPG(fasting plasma glucose)</measure>
    <time_frame>Week 0 to Week 26</time_frame>
    <description>Change from baseline in FPG after 26 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects with HbA1c&lt;7% and HbA1c≤6.5%</measure>
    <time_frame>Week 0 to Week 26</time_frame>
    <description>Proportion of subjects with HbA1c&lt;7% and HbA1c≤6.5% after 26 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>per-breakfast SMPG</measure>
    <time_frame>Week 0 to Week 26</time_frame>
    <description>Mean and Within-subject variability of pre-breakfast SMPG after 26 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>8-point SMPG profiles</measure>
    <time_frame>Week 0 to Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average daily Insulin dose</measure>
    <time_frame>Week 0 to Week 26</time_frame>
    <description>Average daily Insulin dose after 26 weeks of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects requiring rescue therapy during treatment</measure>
    <time_frame>Week 0 to Week 26</time_frame>
    <description>Proportion of subejcts requiring rescue therapy during 26 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of adverse events</measure>
    <time_frame>Week 0 to Week26 +14 days follow-up</time_frame>
    <description>Severity (mild, moderate and severe) is assessed by investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and rate of Hypoglycemic events</measure>
    <time_frame>Week 0 to Week 26+14 days follow-up</time_frame>
    <description>Incidence and rate of of Hypoglycemic events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in weight</measure>
    <time_frame>Week 0 to Week 26</time_frame>
    <description>Change from baseline in weight after 26weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-drug Antibodies</measure>
    <time_frame>Week 0 to Week26 + 14 days follow-up</time_frame>
    <description>Number of subjects with Positive Anti-drug Antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum INS068 concentration</measure>
    <time_frame>Week 0 to Week 26</time_frame>
    <description>To evaluate PK of INS068</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in scores of diabetes treatment satisfaction questionnaire status version (DTSQs)</measure>
    <time_frame>Week 0 to Week 26</time_frame>
    <description>Change from baseline in scores of DTSQs after 26 weeks of treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>INS068</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>IGlar</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INS068 injection</intervention_name>
    <description>INS068 injected subcutaneously once daily. Treat-to-target dose titration during the trial</description>
    <arm_group_label>INS068</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Glargine</intervention_name>
    <description>Insulin Glargine injected subcutaneously once daily. Treat-to-target dose titration during the trial</description>
    <arm_group_label>IGlar</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosed with type 2 diabetes≥ 6 months;&#xD;
&#xD;
          2. HbA1c 7.0% ~ 10.0% (Both inclusive) at screening;&#xD;
&#xD;
          3. Treated with Basal insulin ≥10U /day for at least 8 weeks prior to screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known or suspected allergy or intolerance to investigational medicinal products or&#xD;
             related products.&#xD;
&#xD;
          2. Hospitalization for diabetic ketoacidosis or hyperglycemic hyperosmolar state within&#xD;
             the previous 6 months.&#xD;
&#xD;
          3. Potentially unstable diabetic retinopathy or macular degeneration that requires&#xD;
             treatment (e.g., laser, surgical, or injectable medications) within the previous 6&#xD;
             months.&#xD;
&#xD;
          4. Received premixed insulin, mealtime insulin, or insulin pump therapy within 8 weeks&#xD;
             prior to screening.&#xD;
&#xD;
          5. Participated in clinical trials of any approved or unapproved investigational&#xD;
             drug/treatment within the previous 1 month or 5 half-life period, whichever is longer,&#xD;
             prior to screening.&#xD;
&#xD;
          6. Women who are pregnant, breastfeeding or planning to conceive, or women of&#xD;
             childbearing potential are reluctant to use appropriate contraception during the trial&#xD;
             and for at least 14 days after the last dose of the investigational medicinal drug;&#xD;
             Anycircumstances that the investigator judges might not be suitable to participate in&#xD;
             the trial..&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Miaomiao Shi</last_name>
    <phone>+8618036617171</phone>
    <email>miaomiao.shi@hengrui.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhongshan Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Xiaoying Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>January 19, 2023</study_first_submitted>
  <study_first_submitted_qc>January 19, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2023</study_first_posted>
  <last_update_submitted>May 5, 2023</last_update_submitted>
  <last_update_submitted_qc>May 5, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

